Aduro Biotech, Inc. (ADRO) Insider Jennifer Lew Sells 6,600 Shares

Aduro Biotech, Inc. (NASDAQ:ADRO) insider Jennifer Lew sold 6,600 shares of the stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $8.95, for a total value of $59,070.00. Following the sale, the insider now owns 68,938 shares of the company’s stock, valued at approximately $616,995.10. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jennifer Lew also recently made the following trade(s):

  • On Monday, October 2nd, Jennifer Lew sold 6,600 shares of Aduro Biotech stock. The shares were sold at an average price of $10.61, for a total value of $70,026.00.
  • On Friday, September 1st, Jennifer Lew sold 6,600 shares of Aduro Biotech stock. The shares were sold at an average price of $11.70, for a total value of $77,220.00.

Shares of Aduro Biotech, Inc. (NASDAQ:ADRO) traded down $0.20 during mid-day trading on Friday, hitting $8.80. The company’s stock had a trading volume of 373,989 shares, compared to its average volume of 406,264. Aduro Biotech, Inc. has a 52 week low of $6.01 and a 52 week high of $14.85.

Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.03). Aduro Biotech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The firm had revenue of $3.79 million during the quarter, compared to the consensus estimate of $4.04 million. During the same quarter in the prior year, the business posted ($0.54) EPS. Aduro Biotech’s revenue was up .0% compared to the same quarter last year. sell-side analysts expect that Aduro Biotech, Inc. will post -1.28 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Aduro Biotech, Inc. (ADRO) Insider Jennifer Lew Sells 6,600 Shares” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://sportsperspectives.com/2017/11/18/aduro-biotech-inc-adro-insider-jennifer-lew-sells-6600-shares.html.

Several hedge funds have recently made changes to their positions in ADRO. Bank of New York Mellon Corp lifted its position in shares of Aduro Biotech by 3.8% in the 1st quarter. Bank of New York Mellon Corp now owns 148,166 shares of the biotechnology company’s stock worth $1,593,000 after acquiring an additional 5,470 shares during the period. Parametric Portfolio Associates LLC lifted its position in shares of Aduro Biotech by 15.9% in the 1st quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 2,119 shares during the period. American International Group Inc. lifted its position in shares of Aduro Biotech by 7.1% in the 1st quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock worth $235,000 after acquiring an additional 1,447 shares during the period. Vanguard Group Inc. lifted its position in shares of Aduro Biotech by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 2,382,916 shares of the biotechnology company’s stock worth $25,617,000 after acquiring an additional 48,840 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Aduro Biotech by 6.0% in the 1st quarter. Geode Capital Management LLC now owns 262,809 shares of the biotechnology company’s stock worth $2,825,000 after acquiring an additional 14,946 shares during the period. Institutional investors own 33.63% of the company’s stock.

Several brokerages recently weighed in on ADRO. HC Wainwright set a $18.00 target price on Aduro Biotech and gave the company a “buy” rating in a research note on Wednesday, November 1st. Oppenheimer Holdings, Inc. began coverage on Aduro Biotech in a research note on Monday, October 30th. They set a “buy” rating and a $15.00 target price for the company. William Blair restated an “outperform” rating on shares of Aduro Biotech in a research note on Monday, October 2nd. BidaskClub downgraded Aduro Biotech from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th. Finally, Canaccord Genuity set a $30.00 target price on Aduro Biotech and gave the company a “buy” rating in a research note on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Aduro Biotech has a consensus rating of “Buy” and a consensus target price of $19.14.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply